IPO - Profile


We are a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Synthetic lethality represents a clinically validated approach to drug development and arises when there is a deficiency in either of two conditions that are tolerable alone in cells but lethal together. Our lead program, CYT-0851, as well as our next generation drug candidate CYT-1853, exploits a novel gain-of-function synthetically lethal relationship between overexpression of a More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$18.00 7,400,000 Positive High 22.45%

Offering Team

  • Legal counsel
  • Davis Polk & Wardwell LLP
  • Auditors
  • Ernst & Young LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 17 Jun, 2021

Offer 18 Jun, 2021

Look Ahead

Lock Up Expiry Dec 18, 2021

IPO Terms

Offer Price $18.00
Offer Size 7M

Market Sentiments

Stock Price